Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrochlorothiazide and metformin crossover study to reduce tolvaptan-related aquaresis in ADPKD
NL-OMON46358Phase 2Active, not recruiting
- Sponsor
- Nefro-NL
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydrochlorothiazide, metformin and tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (6 arms), sponsored by Nefro-NL. Primary endpoint: Change in 24-hour urine volume. Started Oct 2018; status: active, not recruiting.
02
Drugs
hydrochlorothiazidemetformintolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON46358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46358.